Roger G. Finch

726 total citations
22 papers, 533 citations indexed

About

Roger G. Finch is a scholar working on Epidemiology, Pharmacology and Applied Microbiology and Biotechnology. According to data from OpenAlex, Roger G. Finch has authored 22 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 8 papers in Pharmacology and 6 papers in Applied Microbiology and Biotechnology. Recurrent topics in Roger G. Finch's work include Antibiotics Pharmacokinetics and Efficacy (8 papers), Antibiotic Use and Resistance (6 papers) and Pneumonia and Respiratory Infections (5 papers). Roger G. Finch is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (8 papers), Antibiotic Use and Resistance (6 papers) and Pneumonia and Respiratory Infections (5 papers). Roger G. Finch collaborates with scholars based in United Kingdom, United States and Australia. Roger G. Finch's co-authors include Joshua P. Metlay, Peter Davey, M. P. Glauser, Mark Woodhead, Paul Williams, S.P. Denyer, L. G. Thijs, Charles L. Sprung, Keryn Christiansen and John H. Powers and has published in prestigious journals such as JAMA, Nature Reviews Microbiology and The American Journal of Medicine.

In The Last Decade

Roger G. Finch

20 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roger G. Finch United Kingdom	12	202	177	133	124	124	22	533
Michael Oinonen United States	12	173 0.9×	228 1.3×	110 0.8×	135 1.1×	151 1.2×	17	521
S.L. Schabowski United States	4	159 0.8×	262 1.5×	178 1.3×	70 0.6×	129 1.0×	4	684
Edit Hajdú Hungary	13	221 1.1×	192 1.1×	103 0.8×	67 0.5×	100 0.8×	65	548
Gail S. Itokazu United States	10	171 0.8×	210 1.2×	184 1.4×	182 1.5×	82 0.7×	17	561
Johan Struwe Sweden	12	178 0.9×	198 1.1×	163 1.2×	44 0.4×	161 1.3×	29	503
A.M. Rogues France	14	154 0.8×	220 1.2×	235 1.8×	80 0.6×	75 0.6×	24	560
Marvin J. Bittner United States	13	182 0.9×	73 0.4×	82 0.6×	128 1.0×	240 1.9×	26	531
Hisham Ziglam United Kingdom	13	177 0.9×	114 0.6×	70 0.5×	76 0.6×	159 1.3×	32	538
Çağrı Büke Türkiye	11	171 0.8×	211 1.2×	136 1.0×	53 0.4×	111 0.9×	22	550
S. Harbarth Switzerland	12	237 1.2×	215 1.2×	164 1.2×	89 0.7×	274 2.2×	13	699

Countries citing papers authored by Roger G. Finch

Since Specialization

Citations

This map shows the geographic impact of Roger G. Finch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger G. Finch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger G. Finch more than expected).

Fields of papers citing papers by Roger G. Finch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger G. Finch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger G. Finch. The network helps show where Roger G. Finch may publish in the future.

Co-authorship network of co-authors of Roger G. Finch

This figure shows the co-authorship network connecting the top 25 collaborators of Roger G. Finch. A scholar is included among the top collaborators of Roger G. Finch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger G. Finch. Roger G. Finch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Metlay, Joshua P., et al.. (2006). Antimicrobial Drug Resistance, Regulation, and Research1. Emerging infectious diseases. 12(2). 183–190. 33 indexed citations

Metlay, Joshua P., et al.. (2006). Antimicrobial Drug Resistance, Regulation, and Research1. Emerging infectious diseases. 12(2). 183–190. 1 indexed citations

Finch, Roger G.. (2004). Antibiotic resistance: a view from the prescriber. Nature Reviews Microbiology. 2(12). 989–994. 24 indexed citations

Finch, Roger G., et al.. (2004). Educational interventions to improve antibiotic use in the community: report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002. The Lancet Infectious Diseases. 4(1). 44–53. 143 indexed citations

Ziglam, Hisham & Roger G. Finch. (2002). Penicillin-resistant pneumococci—implications for management of community-acquired pneumonia and meningitis. International Journal of Infectious Diseases. 6. S14–S20. 7 indexed citations

Davies, Geraint & Roger G. Finch. (2001). Fever of unknown origin. Clinical Medicine. 1(3). 177–179. 1 indexed citations

Finch, Roger G.. (2000). Gemifloxacin. Drugs. 59(5). 1148–1148. 1 indexed citations

Rubinstein, Ethan, Keith P. Klugman, S. Ragnar Norrby, et al.. (1998). Regional considerations in the use of broad-spectrum quinolones. Drugs & Therapy Perspectives. 12(8). 22–22. 1 indexed citations

Finch, Roger G. & Mark Woodhead. (1998). Practical Considerations and Guidelines for the Management of Community-Acquired Pneumonia. Drugs. 55(1). 31–45. 52 indexed citations

10.

Finch, Roger G.. (1996). Antibacterial Activity of Quinupristin/Dalfopristin. Drugs. 51(Supplement 1). 31–37. 50 indexed citations

11.

Sprung, Charles L., Roger G. Finch, L. G. Thijs, & M. P. Glauser. (1996). International sepsis trial (INTERSEPT). Critical Care Medicine. 24(9). 1441–1447. 35 indexed citations

12.

Finch, Roger G.. (1995). Pneumonia: The Impact of Antibiotic Resistance on Its Management. Microbial Drug Resistance. 1(2). 149–158. 8 indexed citations

13.

Finch, Roger G.. (1995). The Role of New Quinolones in the Treatment of Respiratory Tract Infections. Drugs. 49(Supplement 2). 144–151. 20 indexed citations

14.

Finch, Roger G.. (1993). The Withdrawal of Temafloxacin. Drug Safety. 8(1). 9–11. 16 indexed citations

15.

Finch, Roger G., et al.. (1993). Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. Journal of Antimicrobial Chemotherapy. 31(6). 927–937. 53 indexed citations

16.

Finch, Roger G.. (1990). Third-generation cephalosporins in the treatment of rare infections. The American Journal of Medicine. 88(4). S25–S31. 3 indexed citations

17.

Wilcox, Mark H. & Roger G. Finch. (1990). Is oral acyclovir effective in preventing postherpetic neuralgia?. Infectious Diseases Newsletter. 9(9). 67–68. 1 indexed citations

18.

Williams, Paul, S.P. Denyer, & Roger G. Finch. (1988). Protein antigens of Staphylococcus epidermidis grown under iron-restricted conditions in human peritoneal dialysate. FEMS Microbiology Letters. 50(1). 29–33. 32 indexed citations

19.

Finch, Roger G.. (1980). Ludwig's Angina. JAMA. 243(11). 1171–1171. 36 indexed citations

20.

Finch, Roger G.. (1978). Treatment of Lancefield group B streptococcal infections. Journal of Antimicrobial Chemotherapy. 4(3). 198–199. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact